A Case Study to Assess the Risk of Cardio metabolic Side Eff | 92332

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

A Case Study to Assess the Risk of Cardio metabolic Side Effects in Patients Receiving Atypical Antipsychotics Particularly Resperidone and Clozapine

Author(s): P Kanmani*, Sankar A, Umashankar, Aravind Raj S, Goutham kumar A P and K Padmalatha


The Atypical antipsychotics (AAPs) are usually associated with increased risk of weight gain and increased incidence of metabolic side effects particularly impaired glucose tolerance, weight gain, dyslipidemia. Epidemiological, cross-sectional and prospective studies suggest that two of the AAPs, resperidone and clozapine, cause the most dramatic weight gain and metabolic impairments including increased fasting glucose, insulin resistance incidence and raised triglycerides levels. Comparing to other AAPs both resperidone and clozapine exhibit a particularly high antagonistic affinity for histamine and muscarinic receptors which have been the main cause reported for increase in weight gain and the development glucose abnormalities. In this study we studied about the cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and metabolic syndrome).

Share this article